



Biotech Daily

Tuesday February 17, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: TISSUE THERAPIES UP 9%, OPTISCAN DOWN 11%**
- * **IMMURON APPOINTS BEIJING'S LINKER FOR CHINA SALES**
- * **PROGEN RECEIVES \$854k FEDERAL R&D TAX REFUND**
- * **IDT H1 REVENUE \$6m, LOSS UP 42% TO \$3m**
- * **ITL H1 REVENUE UP 9% TO \$14m, PROFIT UP 34% TO \$1.6m**
- * **ANTEO H1 REVENUE FLAT AT \$1.8m, LOSS UP 265% TO \$2.3m**
- * **NANOSONICS PLEADS SCHULTZ, SALES TO ASX 26% QUERY**
- * **CYNATA REQUESTS MANUFACTURING TRADING HALT**
- * **CLIFFORD EU INCREASES, DILUTED TO 9% OF NUSEP**

MARKET REPORT

The Australian stock market fell 0.52 percent on Tuesday February 17, 2015 with the S&P ASX 200 down 30.5 points to 5,858.2 points. Ten of the Biotech Daily Top 40 stocks were up, 18 fell, 10 traded unchanged and two were untraded.

Tissue Therapies was the best, up two cents or 9.1 percent to 24 cents with 1.4 million shares traded.

Universal Biosensors climbed 6.25 percent; Circadian and Medical Developments were up more than five percent; Starpharma was up 4.85 percent; Ellex was up 3.2 percent; Clinuvel and Osprey rose more than two percent; with Benitec, Cochlear and Viralytics up more than one percent.

Optiscan led the falls, down 1.2 cents or 11.4 percent to 9.3 cents with 14.4 million shares traded, followed by Uscom down 10 percent to 18 cents with 1,000 shares traded.

IDT lost 6.9 percent; Genetic Technologies was down 5.9 percent; Admedus, Alchemia and Analytica fell more than four percent; Cellmid, Impedimed, Nanosonics and Prana were down more than three percent; Acrux, Anteo and Phosphagenics shed more than two percent; Bionomics, Oncosil and Pharmaxis were down more than one percent; with CSL and Sirtex down by less than one percent.

IMMURON

Immuron says the Beijing-based Linker Holdings will market, distribute and sell its Travelan for travellers' diarrhoea in the China, Hong Kong and Macau.

Immuron said that Linker would market Travelan as a functional food and a dietary supplement and would comply with specified undisclosed annual minimum purchases. The company said that Linker's minimum purchase obligations were "a significant increase in the volume of the company's Travelan business and will be measurable in multiples of the company's current volumes".

Immuron said that the Chinese market had the potential "to eclipse the combined global sales of Travelan in all other regions ... [beginning] as soon as Linker attains regulatory approval from the Chinese Food and Drug Administration".

In 2014, Immuron reported \$1,044, 142 in revenue from the sale of good for the 12 months to June 30, 2014.

Linker managing director Joseph Xu said that there was "an increasing demand for functional foods and wellness products such as Travelan, especially in light of its gut and liver health benefits".

Immuron chairman Dr Roger Aston said that Travelan was available in Australia and Canada and China was "a very large market opportunity for the expansion of our global Travelan franchise".

"China is a large and increasingly wealthy market, in which gut and liver health are important concerns," Dr Aston said.

Immuron was up 2.5 cents or 12.2 percent to 23 cents.

PROGEN PHARMACEUTICALS

Progen says it has received \$853,770 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

Progen said the rebate related to expenditure for the year to June 30, 2014

Progen was up one cent or 6.45 percent to 16.5 cents.

IDT AUSTRALIA

IDT says that revenue for the six months to December 31, 2014 was \$6,149,000 with loss up 41.6 percent to \$3,081,000 compared to the previous corresponding period.

Last year, IDT said it had revenue \$6,539,000 for the six months to December 31, 2013 but the company said it had changed accounting practice, adopting Accounting Standards Board rules recognizing costs passed to customers as both revenue and expenses, increasing the previous revenue by \$1,966,000 to \$8,505,000, and implying revenue falls of 5.96 percent under the previous regime and a fall of 27.7 percent under the new policy.

IDT said that most of its revenue was from its CMax clinical trial business at the Royal Adelaide Hospital, but it expected increasing revenues from its generic drug business.

The company said that in December it acquired 23 previously marketed US generic drugs raising \$17,015,000 to fund the acquisition (BD: Nov 3, Dec 18, 2014; Jan 18, 2015).

IDT said that diluted loss per share increased 6.45 percent from 3.1 cents in the previous year to 3.3 cents for the six months to December 31, 2014.

The company said it had cash and cash equivalents of \$53,000 at December 31, 2014, compared to \$2,415,000 at June 30, 2014.

IDT said that net tangible assets per share fell 80 percent from 55 cents at December 31, 2013 to 11 cents at December 31, 2014.

IDT fell one cent or 6.9 percent to 13.5 cents.

ITL

ITL says its revenue for the six months to December 31, 2014 fell 9.2 percent to \$14,142,000 taking net profit after tax up 33.9 percent to \$1,628,000.

ITL said it would pay a fully-franked 50 cent dividend with a record date of February 25, 2015, the company's net tangible asset backing per share was up 21.65 percent to 11.8 cents and diluted earnings per share was up 35.7 percent to 1.9 cents for the six months to December 31, 2014, and it held cash and cash equivalents of \$1,623,000 at December 31, 2014 compared to \$122,000 at June 30, 2014.

ITL was untraded at 24 cents.

ANTEO DIAGNOSTICS

Anteo says revenue for the six months to December 31, 2014 was up 0.1 percent to \$1,850,631 with net loss after tax up 264.9 percent to \$2,264,157.

The company said its net tangible assets per share was unchanged at 0.01 cents from June 30, 2014 and diluted loss per share increased 200 percent from 0.1 cents at December 31, 2013 to 0.3 cents at December 31, 2014 and it had cash assets of \$6,851,246 at December 31, 2014 compared to \$7,070,722 at June 30, 2014.

Anteo fell 0.2 cents or 2.1 percent to 9.5 cents.

NANOSONICS

Nanosonics has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price climbed from \$1.465 on February 10 to \$1.85, a 26.3 percent increase, on February 16, 2015 and noted an increase in trading volumes.

Nanosonics said that it released its Appendix C for the three months to December 31, 2014 noting increased sales and had announced that it would begin direct sales of the Trophon EPR in North America (BD: Jan 30, Feb 5, 2015).

Nanosonics fell 5.5 cents or 3.1 percent to \$1.715.

CYNATA THERAPEUTICS

Cynata has requested a trading halt "pending an announcement regarding the status of [its] Cymerus mesenchymal stem cell product manufacture".

Trading will resume on February 19, 2015 or on an earlier announcement.

Cynata last traded at 41 cents.

NUSEP

Director Clifford Eu has increased his holding in Nusep from 12,022,728 shares to 22,115,031 shares but has been diluted from 9.7 percent to 9.3 percent.

The substantial shareholder notice said that Alison Chang converted a convertible note acquiring 6,011,860 shares for \$387,765 or 6.45 cents a share and Mr Eu acquired 46,863 shares in a new issue for \$3,438 or 7.33 cents a share.

The notice said that Mr Eu was Ms Chang's spouse.

Nusep was untraded at 5.1 cents.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily**